Largest ever review finds medicinal cannabis does not effectively treat anxiety, depression, or PTSD

Millions of people use medicinal cannabis specifically because they believe it helps with anxiety, depression, or PTSD. That belief has driven prescriptions, policy changes, and a significant industry in countries where medical use is legal. The largest review of medicinal cannabis research ever conducted has now looked at the evidence behind that belief, and the conclusion is direct: there is no reliable proof that it works for any of those three conditions.

The review, published in The Lancet Psychiatry, synthesized findings from hundreds of clinical studies and trials. Researchers did not find a single condition, among anxiety, depression, and PTSD, where cannabis produced consistent, measurable improvement compared to placebo or established treatments. The authors went further, warning that cannabis may worsen mental health outcomes for some patients and raise the risk of psychosis and dependency with prolonged use.

What the research actually found

The review covered both CBD-dominant and THC-containing products, since patients and prescribers use both for mental health purposes. Across both categories, the evidence for treating anxiety, depression, or PTSD was rated as low quality or inconclusive. Many of the studies that showed positive effects were small, short in duration, lacked proper control groups, or relied on self-reported outcomes rather than standardized clinical measures.

THC, the psychoactive compound in cannabis, showed particular concern in the data. Several studies within the review found that regular THC exposure was associated with increased anxiety symptoms over time, not reduced ones. For people with a genetic predisposition to psychotic disorders, THC use was linked to a meaningfully higher rate of psychosis onset. The researchers noted that these risks are often absent from conversations between patients and prescribers, partly because prescribers in many jurisdictions receive limited training on cannabis pharmacology.

Why so many patients report it helps

This is the part that makes the conversation complicated. Patient surveys consistently show high satisfaction with medicinal cannabis for mental health. A 2022 survey published in the Journal of Psychoactive Drugs found that around 70% of medical cannabis users reported improvement in anxiety symptoms. The Lancet review does not dismiss those experiences, but it does explain the gap: subjective relief and clinical efficacy are not the same thing.

Cannabis produces sedation and euphoria in many users, which can feel like anxiety relief in the short term. That feeling is real. What the clinical data does not support is whether it represents actual improvement in anxiety disorder severity, or whether it creates a dependency loop where the patient feels worse without cannabis and temporarily better with it. The review authors specifically cited this pattern as a concern for long-term users.

PTSD presents its own complexity. Cannabis is often cited as a sleep aid among PTSD patients, and disrupted sleep is one of the most debilitating symptoms of the condition. Some patients report fewer nightmares. But the review found that even here, the controlled trial data is too thin to draw conclusions about whether cannabis is doing something clinically meaningful or simply sedating patients enough to reduce dream recall.

What treatments the researchers recommend instead

The review authors were specific. For anxiety disorders, cognitive behavioral therapy and SSRI medications have strong evidence bases built over decades of randomized controlled trials. For PTSD, trauma-focused CBT and EMDR, eye movement desensitization and reprocessing, are the two most evidence-supported treatments according to guidelines from the American Psychological Association. For depression, the evidence base for SSRIs, SNRIs, and structured psychotherapy is extensive.

None of those treatments are perfect or universally effective. That gap is part of why patients turn to cannabis. When first-line treatments fail or carry side effects that patients cannot tolerate, alternatives become appealing. The researchers acknowledged this directly but argued that choosing an alternative with no proven efficacy and documented risks is not a neutral decision.

The policy question this raises

Medicinal cannabis is legal in over 40 countries, and mental health indications are among the most common reasons patients are prescribed it. In Australia, anxiety is the most frequently listed condition on medicinal cannabis applications. In the UK, mental health conditions account for a large share of private cannabis clinic prescriptions. These are not fringe uses. They are central to how the medicinal cannabis industry has positioned itself and grown.

The Lancet review authors called for regulatory bodies to reconsider mental health as an approved indication for medicinal cannabis, at least until higher-quality randomized trials produce different results. That is a significant ask given how embedded mental health prescribing has become in several national frameworks. Whether regulators act on it or not, the review gives prescribers concrete grounds to have more cautious conversations with patients who come in specifically seeking cannabis for anxiety, depression, or PTSD.

The review's lead authors have indicated they plan to update the analysis as new trial data emerges, with a particular focus on PTSD given several large trials currently underway in the United States and Canada expected to report results by late 2026.